Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1020P (RNA, U6 small nuclear 1020, pseudogene) is a member of a large family of U6 snRNA pseudogenes found throughout the human genome[2][7]. U6 snRNA is a key component of the spliceosome, a ribonucleoprotein complex essential for pre-mRNA splicing in eukaryotes[1][3]. However, RNU6-1020P is classified as a pseudogene, which means it is a non-functional genomic sequence derived from U6 snRNA genes and does not encode an active RNA product[2][7]. Pseudogenes like RNU6-1020P result from evolutionary processes such as retrotransposition events and are characterized by sequence homology to functional genes but lack regulatory elements or functional transcripts[2][5]. There is no evidence that RNU6-1020P is involved in any cellular processes, disease roles, drug interactions, or serves as a biomarker or therapeutic target[2][7]. Its main relevance is as a marker of genome evolution and retrotransposition activity in mammals[2].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1020, pseudogene (RNU6-1020P).